STAT3 and breast cancer: Since LIFR activates multiple singaling pathways in breast cancer cells [42], we also sought to analyze alterations in STAT3 and AKT signaling in the presence and absence of LIFR inhibition via western blot analysis; however, activation of these pathways was too low at baseline to quantify discernable changes in pSTAT3 and pAKT.